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INTRODUCTION 
Numerous radiotherapy regimes are used for inoperable NSCLC who are not suitable for stereotactic ablative radiotherapy. 
Our centre has used continuous hyperfractionated accelerated radiotherapy (CHART, 54Gy in 36 fractions over 12 days) and 
accelerated hypofractionated radiotherapy (55Gy in 20 fractions over 4 weeks) with selection largely down to patient choice (in-
patient vs out-patient treatment). 
This audit reviews patients treated with radical radiotherapy between 2010 - 2015.
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CONCLUSIONS 
This represents a large unselected cohort of patients treated with radical radiotherapy for NSCLC. 
It demonstrates both schedules are deliverable and safe with no statistically significant difference in survival. 
Future dose escalation studies (eg ADSCAN [1]) are required to develop these techniques to match outcomes reported by 
recent concurrent chemo-radiation studies [2].
METHODS 
Case notes and radiotherapy records for all patients receiving radical radiotherapy were retrospectively reviewed. Basic 
patient demographics, tumour characteristics, radiotherapy and survival data were collected. Descriptive statistical analysis 
and Cox regression analysis was performed using SPSS.
Demographic Number of 
patients / Median
Percentage of patients 
(%) / Range
Gender Male 
Female
316 
247
56.1 
43.9
Age Median; Range 71 36-93
Performance  
Status
0 
1 
2 
3 
Unknown
94 
203 
123 
9 
134
16.7 
36.1 
21.8 
1.6 
23.8
FEV1, L Median; Range 
Unknown
1.6!
269
0.6-3.67!
47.8
Site of 
Primary
Central 
Right 
Left 
Unknown
4 
308 
247 
4
0.7 
54.7 
43.9 
0.7
Histology Squamous Cell 
Adenocarcinoma 
Other histology 
No histology
264!
144!
38!
117
46.9 
25.6 
6.7 
20.8
Stage 
(TNM v7)
1 
2 
3 
4 
Unknown
171!
77!
281!
33!
1
30.4!
13.7!
49.9!
5.9!
0.2
PET 
performed?
Yes 
No
532!
31
94.5!
5.5
23%
25%
52%
Local
Distant
Both
13%
29%
50%
8%
CR
PR
SD
PD
3%
29%
2%
1%
65%
No Chemo
Yes - Stage 1
Yes - Stage 2
Yes - Stage 3
Yes - Stage 4
40%
60%
Hypofractionated
CHART
Stage I NSCLC

1 Year OS = 79.5%

2 Year OS = 60.6%

3 Year OS = 40.9%

4 Year OS = 32.8%

5 Year OS = 20.0%
Stage III NSCLC

1 Year OS = 74.5%

2 Year OS = 43.5%

3 Year OS = 25.0%

4 Year OS = 13.3%

5 Year OS = 10.6%
Overall survival stratiÞed by histology
Overall survival stratiÞed by stage for 
stage I + III
Overall survival stratiÞed by site of 
recurrence
Overall survival stratiÞed by response
RESULTS - Outcome 
Median disease-free 
survival was 19 months. 
Median overall survival 
of 22.5 months, with a 
6.5% 90-day mortality 
rate. 
Median OS 
was 31 and 20 
months 
respectively 
for stage I and 
III NSCLC.
On Univariate Analysis 
Histology: p=0.000

Stage: p=0.001

Response: p=0.000

Recurrence: p=0.022

Site of recurrence: p=0.000

Gender: p=0.101

Performance status: p=0.512

Chemotherapy: p=0.762

Radiotherapy regimen: p=0.736

On Multivariate Analysis 
Performance status: p=0.008

Histology: p=0.003

Stage: p=0.002

Chemotherapy: p=0.002

Response: p=0.000

Recurrence: p=0.000

Gender: p=0.844

Age: p=0.304

Radiotherapy regimen: p=0.945
Site of recurrenceResponse Rate
Disease free survival for the population as a whole
RESULTS - Demographics 
563 patients received radical radiotherapy between 2010-15. 
 Radiotherapy Regimen       Prior Chemotherapy 
99.1% completed their prescribed radiotherapy treatment.

